Charles Schwab Investment Management Inc. Has $23.45 Million Stock Holdings in LivaNova PLC $LIVN

Charles Schwab Investment Management Inc. decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 1.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 597,093 shares of the company’s stock after selling 9,267 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.10% of LivaNova worth $23,454,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of LIVN. UMB Bank n.a. raised its holdings in LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company’s stock worth $33,000 after buying an additional 647 shares during the last quarter. CWM LLC lifted its position in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after purchasing an additional 299 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after purchasing an additional 1,441 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its position in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock valued at $173,000 after purchasing an additional 290 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Wolfe Research raised shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research report on Tuesday, May 20th. Finally, Barclays dropped their price target on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, LivaNova has an average rating of “Buy” and an average target price of $59.29.

LivaNova Stock Performance

Shares of LIVN stock opened at $53.39 on Thursday. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -13.72 and a beta of 0.92. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35. The firm’s 50-day simple moving average is $46.09 and its two-hundred day simple moving average is $42.98.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.84 by $0.21. The business had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.93 earnings per share. As a group, equities analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.